2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-144735
    Anti-inflammatory agent 14 894496-27-6 98%
    Anti-inflammatory agent 14 (compound 28) is an anti-inflammatory agent, with a MIC50 of 2 μM for Mtb H37Rv.
    Anti-inflammatory agent 14
  • HY-144737
    Anti-inflammatory agent 15 474516-87-5 98%
    Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 15 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 2.3 and 7.8 μM, respectively. Anti-inflammatory agent 15 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 15 can be used for tuberculosis (TB) research.
    Anti-inflammatory agent 15
  • HY-144738
    Dual FAAH/sEH-IN-1 2756099-59-7 98%
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.
    Dual FAAH/sEH-IN-1
  • HY-144773
    Loxoprofenol-SRS 83648-76-4 98%
    Loxoprofenol-SRS, an active metabolite of Loxoprofen, is a new intravenous NSAID. Loxoprofenol-SRS exhibits significantly stronger anti-inflammatory and analgesic activities.
    Loxoprofenol-SRS
  • HY-144781
    CXCR2 antagonist 5 3037517-09-9 98%
    CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity (IC50=0.013 µM) and calcium mobilization (IC50=0.1 µM)[ 1].
    CXCR2 antagonist 5
  • HY-144783
    CXCR2 antagonist 6 98%
    CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist. CXCR2 antagonist 6 shows potent CXCR2 binding affinity (IC50=0.044 µM) and calcium mobilization (IC50=0.66 µM)[ 1].
    CXCR2 antagonist 6
  • HY-144784
    CXCR2 antagonist 7 98%
    CXCR2 antagonist 7 (compound 19) is a potent CXCR2 antagonist. CXCR2 antagonist 7 shows potent CXCR2 binding affinity (IC50=0.044 µM) and calcium mobilization (IC50=0.66 µM)[ 1].
    CXCR2 antagonist 7
  • HY-144812
    Gü1303 1043922-53-7 98%
    Gü1303 is a potent, reversible, slow-binding cathepsin K (CatK) inhibitor with a Ki of 0.91 nM for mature CatK (mCatK). Gü1303 suppresses the autocatalytic activation of the cathepsin K zymogen.
    Gü1303
  • HY-145026
    ERK1/2 inhibitor 4 2490396-99-9 98%
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1).
    ERK1/2 inhibitor 4
  • HY-145028
    ERK1/2 inhibitor 6 2634816-13-8 98%
    ERK1/2 inhibitor 6 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 6 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021063335A1, compound 1).
    ERK1/2 inhibitor 6
  • HY-145035
    HPK1-IN-9 2734168-78-4 98%
    HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) .
    HPK1-IN-9
  • HY-145087
    NP3-146 210826-47-4 98%
    NP3-146 is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 shows potent inhibitory activity against IL-1β release with an IC50 value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 can be used for the research of inflammatory diseases.
    NP3-146
  • HY-145109
    HPK1-IN-20 2561490-78-4 98%
    HPK1-IN-20 (Compound 106) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor.
    HPK1-IN-20
  • HY-145126
    CP-628006 305822-08-6 98%
    CP-628006, a small molecule CFTR potentiator, restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    CP-628006
  • HY-145248
    Biotin-PEG7-C2-NH-Vidarabine-S-CH3
    Biotin-PEG7-C2-NH-Vidarabine-S-CH3 is a PEG-based linker that incorporates adenosine analog Vidarabine. Vidarabine is an antiviral agent which is active against herpes simplex and varicella zoster viruses.
    Biotin-PEG7-C2-NH-Vidarabine-S-CH3
  • HY-145253
    Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH
    Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
    Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH
  • HY-145254
    Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH 98%
    Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
    Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH
  • HY-145255
    Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH
    Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
    Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH
  • HY-145352
    ChemR23-IN-2 2465086-50-2 98%
    ChemR23-IN-2 is a potent and orally efficacious ChemR23 inhibitor with an IC50 value of 3.2 nM.
    ChemR23-IN-2
  • HY-145406
    IHCH-3064 2420562-65-6 98%
    IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent.
    IHCH-3064
Cat. No. Product Name / Synonyms Application Reactivity